US2190137A - Soluble protamine insulin - Google Patents

Soluble protamine insulin Download PDF

Info

Publication number
US2190137A
US2190137A US152995A US15299537A US2190137A US 2190137 A US2190137 A US 2190137A US 152995 A US152995 A US 152995A US 15299537 A US15299537 A US 15299537A US 2190137 A US2190137 A US 2190137A
Authority
US
United States
Prior art keywords
insulin
protamine
soluble
units
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US152995A
Inventor
Sahyun Melville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frederick Stearns & Co
Original Assignee
Frederick Stearns & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frederick Stearns & Co filed Critical Frederick Stearns & Co
Priority to US152995A priority Critical patent/US2190137A/en
Application granted granted Critical
Publication of US2190137A publication Critical patent/US2190137A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins

Definitions

  • This invention relates to water soluble protapost-prandial rise in thejblood sugar takesfplace mine'insulin and the process of producing the afterfits" administration necessitating a slmul same, l V V taneous injectionof regular insulin to compen-
  • protamine insulin can-be profe for thi defi i y.
  • phosphate buffer must be added for. the adjustment of the hydrogen ion concentration.
  • Example I To a known concentration of insulin"5.0 milligrams of a highly purified protamine fol-every 100units of insulin are added. The hydrogen ion concentration need not be carefully adjusted, other than to maintain an acidity slightly below that of the precipitation of insulin, for example, The mixture is then carefully warmed in a water bath'below the temperature at which the insulin protein would bedenatured. I have found that temperatures of about 55-55" C. are suitable for this and that about 2 or 3 hours are need at such temperatures. The volume is adjusted by adding an isotonic medium such as water and glycerine, for example, to produce the desired concentration of units of insulin per 1 cc.
  • an isotonic medium such as water and glycerine
  • the material is next rendered sterile by any or the usual methods.
  • a solution of crystalline insulin approximately 5 milligrams of pure protamine to every 190 ofinsulin are added, followedby a small quantity of an acid phosphate, such as sodium or potassium di-hydrogenphosphate, and about 5.2 mini gram of zinc.
  • Thepurposeof the latter is to 1 preventdeterioration of the potency of the final product.
  • the mixture is then heated to about 50 to 55 0.. for 2 or 3 hours, then kept in an incubator at about 50 C. for approximately as to 48 hours, and isthenbrought to the desired 7 concentration and 'sterilized.
  • protamine-insulin that is entirely water soluble which comprises combining protamine and insulin in the proportions of at least 2.5 mg. of protamine to V 100 units of insulin in an aqueous medium whose pH is below 3.5 in the presence of about 0.2 mg. of zinc per 100 units of insulin at a temperature below about 55 C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

Pi nemsisnn; it 2,190,137
SOLUBLE PR TA INE INSULIN 3 .t Melville Sahyun, Detroit,,Mioh., assignor to' FrederickStearns 85 Company, Detroit, Mich., a
corporation oLMichigan' o No Drawings Application July 10, 1937, 1 lSerial'No. 152,995 N m6 Claims; (01.167-75) p .1 A This invention relates to water soluble protapost-prandial rise in thejblood sugar takesfplace mine'insulin and the process of producing the afterfits" administration necessitating a slmul same, l V V taneous injectionof regular insulin to compen- By this invention protamine insulin can-be profe for thi defi i y. duced in a very rapid and convenient manner 1 (e) In view of the factthat such aprecipi= 5 without requiring expensive apparatus and withtated material has a hydrogen ion concentration Outas much difliculty as is experienced in prosuitable for bacterial growth, the utmost preducing insoluble protamine insulin that is now auti n is necessary t s e mple Sterility. on the market. The protamine insulin of this infor unless th fi P p t is perfectly clear, 10' 'vention possesses the prolonged hypoglycemi efit; is extremely diflicult to know, by mere inspec- 10 feet, that has been, observed t msoluble s tion of the vial, whether or not the material has tamine insulin and at thesame time it'has all becQme contaminated y a. the advantages due to its being soluble in water. In the preparation i the precipitated pr a- It is w n known t t t mi g t of mine-insulin complex of the prior art, 0.75 tol.25 insulin causes a very rapid lowering or blood mi a s o p ne we eu d pe 100 units sugar with subsequent rapid return to the initial of insulin. diSSOll/ed. in a and about 1 0f level., From clinical and animal experimentaa 2 P cent Solution q 'd hydrogen Ph tionllt has been found thatthe effect of insulin photo was added to raisethe oge ion conon blood sugar does not usually last more than fi l' 0f insulin a d nr t 2o 6 or 'lhours, so that many diabetic patients need l f fi ut P t was found t t Such 20 V to be given as many asfour injections of insulin I addltlon O Protamine o insulin. n the s b daily. investigators have therefore been work quell? injection as a clear Solution d P omg diligently w d t preparation of a mduce a more prolonged action on the blood sugar mm t t, would exert prolgnged hypogwcemic than that of regular insulin but that the product effect in the system, thus reducing the number had to beprecimtated in order for i o pr duce 5 of necessary daily injections. Emulsions of ina prolonged hypoglycemic e c This precipi sulin with oil have been tried and have been found ated prod 15 I10W on h e to produce a somewhat more prolonged hypo- By the P t invention I use a method that glycemic effect than regular insulin. However, enables me to P e a C Solutionflf 1 18111 since such preparations were nothomogeneous Protamine complex P ep that is 9411116317 they were not satisfactory to the clinicians and as rapid initially in its c n s regular insulin the diabetic patients. and yet as prolonged in its effect as the .preci- It has also been known for some time that so- Pita/Bed -p a ne; caged t m insulin could be produced by g In myinvestigations of the efiect of protamine' precipitating insulin from a water solution by the on insulin with reference to the prolongation of 35 addition of protamineand that the precipitated the action of the latter, I have found that by insulin-protainine complex, when administered using 2.5 to.'5.0 rnilligramsof protamine to 100 to patients, acted more slowly on the blood sugar units of water'solution of insulin, and by heating of t sy m d maintained a w lood su the insulin and protami'ne and allowingjthe mix- 40 level a longer Period tune than the 8 ture to stand for several days, a complex or l (1085- of i @aflvantages of. preparation is formed that has an initial rapid suchprec pitated protaminee nsulln preparations hypoglmemic effect and yet the duration of or complexes are: I hypoglycemia is greatlyprolonged. Slim.
(a) The are not 'sable over lon riod of V 7, time and {heremre exmmtma'n i g be preparation has been carefully studiedon animals e i and human beings and has been found to possess placed on each package of them.
(1,), such preparations do not remain hom0ge the following distinct advantages over other pronegus upon standing atroom temperature, and tamine-insulin preparations now on the market: quite often a sticky material is formed on the p (a) This new preparation f a lear insulinside f the containers, 7 V protamine solution is permanently stable and 50 (c) It has ben observed that nodules are often therefore does. not require an expiration date to found at the site of injection 01' such protaniinebe placed on the packages thereof. insulin preparations. (b) Its initial action is rapid so that this clear (d) The action of the precipitated protamineinsulin-protamine begins to take eflect at once insulin complex is slow, so that a considerable upon administration, thus eliminating the neces- 55 careful adjustment of the hydrogen ion concen-- tration. I
The danger of bacterial contamination is considerably reduced. My preparation issterilized by'one filtration, whereas withthe prior product, that is, a precipitated or cloudy insulinprotamine, one must'sterilize insulin or'insulin and protamine and introduce them into a sterile vial and then into this vial a sterile solution of pH 3.0 to 3.5.
phosphate buffer must be added for. the adjustment of the hydrogen ion concentration.
(I) The subcutaneous administration of this 'clear solution of insulin-protamine' does not 'cause the formation of nodules at the site of injection.
The following are givenas specific examples to illustrate the invention, but it is to be understood that the invention is not restricted to the specific details or the exact temperatures, ma-' terials, or proportions thereof that are mentioned:
Example I To a known concentration of insulin"5.0 milligrams of a highly purified protamine fol-every 100units of insulin are added. The hydrogen ion concentration need not be carefully adjusted, other than to maintain an acidity slightly below that of the precipitation of insulin, for example, The mixture is then carefully warmed in a water bath'below the temperature at which the insulin protein would bedenatured. I have found that temperatures of about 55-55" C. are suitable for this and that about 2 or 3 hours are need at such temperatures. The volume is adjusted by adding an isotonic medium such as water and glycerine, for example, to produce the desired concentration of units of insulin per 1 cc.
The material is next rendered sterile by any or the usual methods.
a solution of crystalline insulin, approximately 5 milligrams of pure protamine to every 190 ofinsulin are added, followedby a small quantity of an acid phosphate, such as sodium or potassium di-hydrogenphosphate, and about 5.2 mini gram of zinc. Thepurposeof the latter is to 1 preventdeterioration of the potency of the final product. The mixture is then heated to about 50 to 55 0.. for 2 or 3 hours, then kept in an incubator at about 50 C. for approximately as to 48 hours, and isthenbrought to the desired 7 concentration and 'sterilized.
I claim:
l. The process of producing a protamine-insulin that is entirely water soluble which coo-1 prises combining protamine and insulin the proportionsof at least 2.5 mg. of protamine to 100 units of insulin in an aqueous medium whose pH is below 3.5 at a temperature below about '2. The process of producing a protaminedm sulin that entirely water soluble which'com prises combining protarnine and insulin in the proportions of at least 2.5 mg. of protamine to its units of insulin in an aqueous medium whose pH is below 3.5, and heating to about 50 to 55 C.
3. The process of producing a protarnine in sulin that is entirely water soluble which :o.-"n prises combining protamine and insulin in the proportions of at least 2.5 mg. of protarnine to 100 units of insulin in an aqueous medium whose pH is below 3.5, and heating to about 50 to 55 C. for about 2'or 3 hours.
4. Theprooess of producing a protamine-insulin that is entirely water soluble which comprises combining protamine and insulin in the proportions of at least 2.5 mg. of protamine to V 100 units of insulin in an aqueous medium whose pH is below 3.5 in the presence of about 0.2 mg. of zinc per 100 units of insulin at a temperature below about 55 C.
5. A clear stable solution containing insulin to which has been added from 2.5 mg. to 5 mg. oi protamine for each 100 units of the insulin, said solution having an acidity of about pH 3.0.
6. A clear stable solution containing insulin to which has been added zinc and from 2.5 mg. to 5 mg. of protamine for each 100 units of the insulin, said solution having an acidity of about pH 3.0.
MCELVILLE SAHYUN.
US152995A 1937-07-10 1937-07-10 Soluble protamine insulin Expired - Lifetime US2190137A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US152995A US2190137A (en) 1937-07-10 1937-07-10 Soluble protamine insulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US152995A US2190137A (en) 1937-07-10 1937-07-10 Soluble protamine insulin

Publications (1)

Publication Number Publication Date
US2190137A true US2190137A (en) 1940-02-13

Family

ID=22545347

Family Applications (1)

Application Number Title Priority Date Filing Date
US152995A Expired - Lifetime US2190137A (en) 1937-07-10 1937-07-10 Soluble protamine insulin

Country Status (1)

Country Link
US (1) US2190137A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574889A (en) * 1947-10-06 1951-11-13 Leo Ab Methylated gelatin-insulin preparation
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574889A (en) * 1947-10-06 1951-11-13 Leo Ab Methylated gelatin-insulin preparation
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution

Similar Documents

Publication Publication Date Title
Moloney et al. Antigenicity of insulin: diabetes induced by specific antibodies
Jaques et al. The identity and origin of the anticoagulant of anaphylactic shock in the dog
Code et al. Importance of vagal innervation in the regulatory effect of acid in the duodenum on gastric secretion of acid
Komano et al. Participation of Sarcophagaperegrina humoral lectin in the lysis of sheep red blood cells injected into the abdominal cavity of larvae
Sayers et al. Effect of adrenotropic hormone on ascorbic acid and cholesterol content of the adrenal.
NO161204B (en) PROCEDURE FOR PREPARING AN INSULIN SOLUTION.
Dam et al. Alimentary exudative diathesis
LEWIS et al. The effect of the adrenal cortex on carbohydrate metabolism
US2882203A (en) Injectable insulin preparation with protracted effect
US2849370A (en) Injectable insulin preparations with protracted effect and process of producing same
McCance et al. Iron excretion and metabolism in man
US2190137A (en) Soluble protamine insulin
US2411897A (en) Pharmaceutical solution
Popp Regression of grafted bone marrow in homologous irradiated mouse chimeras
EP0353861A1 (en) Angiogenesis inhibitor
US3420810A (en) Process for joining the a and b chains of insulin
Bollman et al. Action of glucose and insulin on free amino acids of the dehepatized dog
US2704737A (en) Urea-modified insulin and process for preparing
Parkes et al. The influence of the subcutaneous implantation of tablets of solid insulin on the blood sugar level of the rabbit
EP0001443A1 (en) Agent for the contraception and termination of pregnancy and process for its production
US3326763A (en) Reagent for increasing activity of insulin
Brunschwig et al. Intravenous gelatin
Smith et al. Blood sugar, insulin, and dextrose tolerance in albino rat treated with carbon monoxide
US3208995A (en) Method of depolymerizing alginic acid salts and esters by reaction with no2
JPH06279292A (en) Production of glycogen having physiological activity and physiological activity